P0ABE7 (C562_ECOLX) Escherichia coli
Soluble cytochrome b562 UniProtKBInterProSTRINGInteractive Modelling
128 aa; Sequence (Fasta) ;
23 identical sequences
It is possible new templates exist for this target since these models were created.
Available Structures
306 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Crystal structure of human histamine receptor H3R in complex with antagonist PF03654746 |
Heteromer Q9Y5N1; | 97.17 | 1×1IB; 1×CLR; | |||
| XFEL crystal structure of human melatonin receptor MT2 in complex with 2-phenylmelatonin |
Heteromer P00268; P49286; | 97.17 | 2×JEY; 1×ZN; 1×OLC; | |||
| Structural Insights into the Extracellular Recognition of the Human Serotonin 2B Receptor by an Ant… |
Heteromer P41595; | 96.81 | 1×ERM; | |||
| Crystal structure of 5-HT1B-BRIL and SRP2070_Fab complex |
Heteromer P28222; | 96.91 | 1×ERM; | |||
| Complex structure of angiotensin II type 2 receptor with Fab |
Heteromer P01019; P50052; | 96.74 | ||||
| Crystal structure of AT2R-BRIL and SRP2070_Fab complex |
Heteromer P01019; P50052; | 96.74 | ||||
| SARS-CoV-2 fusion peptide epitope scaffold FP15 bound to DH1058 |
Heteromer | 89.52 | ||||
| Human dopamine D2 receptor in complex with spiperone |
Heteromer P14416; | 97.37 | 1×SIP; | |||
| Complex structure of Ghrelin receptor with Fab |
Heteromer Q92847; | 97.14 | 1×8QX; | |||
| Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in ternary compl… |
Heteromer P55085; | 98.09 | ||||
| The TPP-bound BRIL-SLC19A1/Fab/Nb ternary complex |
Heteromer P41440; | 98.09 | 1×TPP; | |||
| Structure of human Frizzled5 by fiducial-assisted cryo-EM |
Heteromer Q13467; | 97.83 | ||||
| FZD3 in inactive state |
Heteromer Q9NPG1; | 97.83 | ||||
| Cryo-EM structure of inactive FZD1 |
Heteromer Q9UP38; | 97.83 | ||||
| The 5-MTHF-bound BRIL-SLC19A1/Fab/Nb ternary complex |
Heteromer P41440; | 98.09 | 1×THH; | |||
| FZD6 in inactive state |
Heteromer O60353; | 97.83 | ||||
| The BRIL-SLC19A1/Fab/Nb ternary complex |
Heteromer P41440; | 98.09 | ||||
| Cryo-EM structure of ETAR bound with Ambrisentan |
Heteromer P25101; | 97.83 | 1×A1D5J; | |||
| Cryo-EM structure of ETAR bound with Macitentan |
Heteromer P25101; | 97.83 | 1×A1D5I; | |||
| Cryo-EM structure of ETAR bound with Zibotentan |
Heteromer P25101; | 97.83 | 1×A1D5L; | |||
| Cryo-EM structure of GPR55-Fab-Nb-ONO-9710531 complex |
Heteromer Q9Y2T6; | 97.75 | 1×A1L3E; | |||
| Cryo-EM structure of the inactive chemokine-like receptor 1 (CMKLR1) |
Heteromer Q99788; | 98.09 | ||||
| Crystal structure of BRIL and SRP2070_Fab complex |
Heteromer | 98.08 | ||||
| Crystal structure of BRIL in complex with 1b3 Fab |
Heteromer | 98.08 | ||||
| Structure of the N/OFQ Opioid Receptor in Complex with a Peptide Mimetic |
Heteromer P41146; | 97.11 | 2×0NN; 1×OLB; 1×OLA; 1×OLC; | |||
| Molecular mechanism of biased signaling at the kappa opioid receptor |
Heteromer P41145; | 97.47 | 1×IVB; | |||
| Structure of AT118-L Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor and Los… |
Heteromer P30556; | 97.83 | 1×LSN; | |||
| Structure of AT118-H Nanobody Antagonist in Complex with the Angiotensin II Type I Receptor |
Heteromer P30556; | 97.8 | 2×Y01; | |||
| Cryo-EM Structure of GPR61- |
Heteromer Q9BZJ8; | 98.08 | 1×ZOB; | |||
| Crystal structure of BRIL bound to an affinity matured synthetic antibody. |
Heteromer | 98.06 | 2×GOL; 2×FMT; 1×NA; | |||
| cryo-EM structure of a tmFAP |
Heteromer | 97.92 | 1×KY6; | |||
| HMGCR-UBIAD1 Complex State 1 |
Heteromer G3IEF0; P00347; | 98.06 | 6×Y01; 2×AJP; | |||
| HMGCR-UBIAD1 Complex State 2 |
Heteromer G3IEF0; P00347; | 98.06 | 6×Y01; 2×AJP; | |||
| CryoEM structure of human alpha4beta2 nicotinic acetylcholine receptor with varenicline in complex … |
Heteromer P17787; P43681; | 99.01 | 2×NAG; 1×NAG; 4×NAG; 2×QMR; 1×BMA; | |||
| Cryo-EM structure of SNAP-94847-bound MCHR1, S2 state |
Heteromer A0A2R9AFP0; Q99705; | 97.67 | 1×A1D6T; | |||
| Cryo-EM structure of SNAP-94847-bound MCHR1, S1 state |
Heteromer A0A2R9AFP0; | 97.67 | 1×A1D6T; | |||
| Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV026 |
Heteromer P30556; | 98.67 | 1×NAG; 6×OLC; 1×CLR; | |||
| Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to TRV023 |
Heteromer P30556; | 98.68 | 6×OLC; 1×CLR; | |||
| Structure of synthetic nanobody-stabilized angiotensin II type 1 receptor bound to angiotensin II |
Heteromer P01019; P30556; | 98.88 | 1×NAG; 2×CL; | |||
| Structure of nanobody-stabilized angiotensin II type 1 receptor bound to S1I8 |
Heteromer P30556; | 100.0 | 1×NAG; 3×CL; 2×OLC; | |||
| Angiotensin II type 2 receptor with ligand |
Heteromer P01019; P50052; | 100.0 | ||||
| Get3 bound to ADP and the transmembrane domain of the tail-anchored protein Bos1 |
Heteromer A8B3G9; P25385; | 100 | 2×ADP; 1×ZN; 2×MG; | |||
| Crystal structure of Hat1-Hat2-Asf1-H3-H4 |
Heteromer P02309; P39984; P61830; Q12341; Q4WXX5; | 100 | 1×COA; | |||
| Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor |
Heteromer P41145; | 0.0 | 1×CVV; 1×CLR; 1×OLA; | |||
| Bimetallic dodecameric cage design 2 (BMC2) from cytochrome cb562 | homo-12-mer | 81.13 | 12×HEC; 24×HAE; 12×FE; 18×ZN; | |||
| Bimetallic dodecameric cage design 3 (BMC3) from cytochrome cb562 | homo-12-mer | 79.25 | 12×HEC; 21×ZN; 12×FE; 24×HAE; 3×1PE; | |||
| A Zn-mediated tetrahedral protein lattice cage encapsulating a microperoxidase | homo-12-mer | 87.74 | 15×HEM; 12×ACT; 30×ZN; | |||
| Bimetallic dodecameric cage design 1 (BMC1) from cytochrome cb562 | homo-12-mer | 82.08 | 18×ZN; 12×HAE; 12×HEC; 6×FE; | |||
| A Zn-mediated tetrahedral protein lattice cage | homo-12-mer | 87.74 | 12×HEM; 12×ACT; 36×ZN; | |||
| Cryo-EM structure of Bimetallic dodecameric cage design 3 (BMC3) from cytochrome cb562 | homo-12-mer | 79.25 | 12×HEC; 24×HAE; 24×ZN; 8×FE; | |||
| Crystallographic octamer of a metal-free RIDC1 variant bearing two disulfide bonded cysteines | homo-8-mer | 88.68 | 8×HEC; 14×CA; | |||
| Bimetallic hexameric cage design 4 (BMC4) from cytochrome cb562 | homo-6-mer | 79.25 | 6×HEC; 18×ZN; 6×FE; 6×HAE; | |||
| Crystal structure of an engineered Zn-RIDC1 construct with four interfacial disulfide bonds | homo-4-mer | 87.74 | 4×HEM; 4×ZN; 7×SO4; | |||
| Crystal structure of a Zn-bound RIDC1 variant in the presence of reductant | homo-4-mer | 87.74 | 4×ZN; 4×CA; 4×HEC; | |||
| Crystal structure of a Zn-bound RIDC1 variant | homo-4-mer | 87.74 | 5×ZN; 4×HEC; 3×MPD; 1×MRD; 1×EPE; | |||
| Crystal Structure of a Dimeric Cytochrome cb562 Assembly Induced by Copper Coordination | homo-4-mer | 95.28 | 4×CU; 6×CA; 4×HEM; | |||
| Tetrameric Cytochrome cb562 (K34/H59/D62/H63/H73/A74/H77) Assembly Stabilized by Interprotein Zinc … | homo-4-mer | 92.45 | 4×ZN; 5×CA; 4×HEM; | |||
| Disulfide-free, Zn-directed tetramer of the engineered cyt cb562 variant, C96T/A104AB3 | homo-4-mer | 86.79 | 4×HEM; 8×ZN; 5×CL; 4×MG; | |||
| Tetrameric Cytochrome cb562 (H59/D62/H63/H73/A74/H77) Assembly Stabilized by Interprotein Zinc Coor… | homo-4-mer | 93.4 | 4×ZN; 5×CA; 4×HEM; | |||
| Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, C96T/AB5 | homo-4-mer | 85.85 | 4×HEC; 14×ZN; 1×CL; | |||
| Crystal structure of a Co-bound RIDC1 variant | homo-4-mer | 87.74 | 4×HEC; 4×CO; | |||
| Crystal structure of the Zn-induced tetramer of the engineered cyt cb562 variant RIDC-2 | homo-4-mer | 83.96 | 4×HEM; 8×ZN; | |||
| Crystal structure of an engineered metal-free tetrameric cytochrome cb562 complex templated by Zn-c… | homo-4-mer | 88.68 | 4×HEM; | |||
| A tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalently stabilized interf… | homo-4-mer | 88.68 | 4×HEM; 4×ZN; | |||
| Crystal structure of the Zn-RIDC1 complex bearing six interfacial disulfide bonds | homo-4-mer | 87.74 | 4×HEC; 1×P6G; 4×ZN; | |||
| Crystal structure of an engineered metal-free RIDC1 construct with four interfacial disulfide bonds | homo-4-mer | 87.74 | 4×HEM; | |||
| Crystal structure of a metal-free RIDC1 variant | homo-4-mer | 87.74 | 4×HEC; | |||
| Crystallogrpahic tetramer of Zn-bound RIDC1 variant bearing two disulfide bonded cysteines | homo-4-mer | 88.68 | 4×HEC; 3×CA; 10×ZN; | |||
| Crystal structure of an engineered RIDC1 tetramer with four interfacial disulfide bonds and four th… | homo-4-mer | 86.79 | 4×HEM; 6×ZN; | |||
| Crystal structure of the Zn-induced tetramer of the engineered cyt cb562 variant RIDC-1 | homo-4-mer | 89.62 | 4×HEM; 4×ZN; | |||
| Crystal structure of a tetrameric Zn-bound cytochrome cb562 complex with covalently and non-covalen… | homo-4-mer | 88.68 | 4×HEM; 4×ZN; | |||
| Crystal structure of an engineered metal-free RIDC1 variant containing five disulfide bonds. | homo-4-mer | 87.74 | 4×HEC; 2×NA; | |||
| Crystal structure of an engineered protein that forms nanotubes with tunable diameters | homo-4-mer | 85.85 | 4×HEM; 14×ZN; | |||
| Crystal Structure of the Zn-directed tetramer of the engineered cyt cb562 variant, AB3 | homo-4-mer | 86.79 | 4×HEC; 8×ZN; | |||
| Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, AB5 | homo-4-mer | 84.91 | 4×HEC; 8×ZN; 12×CL; | |||
| Crystal structure of a Cu-bound cytochrome cb562 variant in the presence of reductant | homo-4-mer | 87.74 | 4×HEC; 4×CU; | |||
| Crystal structure of the Zn-directed tetramer of the engineered cyt cb562 variant, A104/57G AB3 | homo-4-mer | 83.52 | 4×HEC; 20×CA; 8×ZN; | |||
| Crystal Structure of a 16-Helix Bundle Architecture Produced by the Zinc-Mediated Self Assembly of … | homo-4-mer | 95.28 | 4×HEM; 4×ZN; | |||
| Fe-bound structure of an engineered metal-dependent protein trimer, TriCyt2 | homo-3-mer | 90.57 | 3×HEC; 1×FE2; 1×SO4; | |||
| Crystallographic trimer of metal-free TriCyt2 | homo-3-mer | 90.57 | 3×HEC; 3×MPD; 1×SO4; | |||
| Cu-bound structure of the engineered protein trimer, TriCyt3 | homo-3-mer | 84.91 | 3×HEC; 7×CL; 1×CU; 1×PEG; | |||
| Crystal structure of Ni-bound RIDC1 variant in the presence of reductant | homo-3-mer | 87.74 | 9×NI; 3×TRS; 3×HEC; 3×CL; | |||
| Co-bound structure of an engineered protein trimer, TriCyt3, with delta isomerism at the hexahistid… | homo-3-mer | 84.91 | 3×HEC; 1×CO; 2×CL; 6×MG; | |||
| Mn-bound structure of an engineered protein trimer, TriCyt3 | homo-3-mer | 84.91 | 3×HEC; 4×CA; 1×MN; 4×CL; | |||
| Co-bound structure of an engineered protein trimer, TriCyt3 | homo-3-mer | 84.91 | 3×HEC; 1×CO; 5×CL; | |||
| Crystal Structure of a Trimeric Cytochrome cb562 Assembly Induced by Nickel Coordination | homo-3-mer | 95.28 | 9×NI; 3×HEM; | |||
| Ni-bound structure of an engineered protein trimer, TriCyt3 | homo-3-mer | 84.91 | 3×HEC; 6×NI; 12×CA; 9×CL; | |||
| Crystal structure of a Fe-bound RIDC1 variant in the presence of reductant | homo-3-mer | 87.74 | 3×HEC; 2×FE; 1×1PE; | |||
| Mn-bound structure of a TriCyt3 variant | homo-3-mer | 83.96 | 3×HEC; 1×MN; 5×CL; 9×CA; | |||
| A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Monoclinic Form | homo-3-mer | 93.4 | 3×HEM; 3×PXX; 6×NI; | |||
| Ni-bound structure of an engineered metal-dependent protein trimer, TriCyt1 | homo-3-mer | 93.4 | 3×HEC; 1×NI; 5×NA; 6×CL; 3×MPD; | |||
| Cu-bound structure of an engineered metal-dependent protein trimer, TriCyt1 | homo-3-mer | 93.4 | 3×HEC; 3×CU; 15×CA; | |||
| A Zn-mediated asymmetric trimer of a cytochrome cb562 variant (D74A-RIDC1) | homo-3-mer | 88.68 | 3×HEM; 2×ZN; | |||
| Crystal structure of the high-affinity copper transporter Ctr1 | homo-3-mer | 97.85 | 6×TBR; 3×ZN; | |||
| Crystal structure of the high-affinity copper transporter Ctr1 in complex with Cu(I) | homo-3-mer | 97.85 | 6×CU1; 3×ZN; | |||
| Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the … | homo-2-mer | 89.62 | 2×HEC; 5×CA; 1×CU; | |||
| Co-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 | homo-2-mer | 90.57 | 2×HEC; 2×CO; | |||
| Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presenc… | homo-2-mer | 90.57 | 2×HEC; 2×NI; | |||
| Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the … | homo-2-mer | 89.62 | 2×HEC; 2×NI; | |||
| Zn(II)-bound B2 dimer (H60/H100/H104) formed in Zn(II)//Cu(II) (M1 // M2) condition | homo-2-mer | 93.4 | 2×HEC; 6×ZN; | |||
| Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H63A, crystallized in the … | homo-2-mer | 89.62 | 2×HEC; 2×NI; | |||
| Zn(II)-bound B2 dimer (H60/H100/H104) formed in Cu(II)//Zn(II) (M1 // M2) condition | homo-2-mer | 93.4 | 2×HEC; 6×ZN; | |||
| Heme-Free Cytochrome Variant ApoCyt | homo-2-mer | 95.28 | ||||
| Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presenc… | homo-2-mer | 90.57 | 2×HEC; 2×NI; | |||
| Zn(II)-bound B2 dimer (H60/H100/H104) | homo-2-mer | 93.4 | 2×HEC; 6×ZN; | |||
| Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presenc… | homo-2-mer | 90.57 | 2×HEC; 2×NI; | |||
| Ni-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presenc… | homo-2-mer | 90.57 | 2×HEC; 2×CO; | |||
| Ni-bound crystal structure of the engineered cyt cb562 variant, AB2-H100A, crystallized in the pres… | homo-2-mer | 91.51 | 2×HEC; 1×NI; | |||
| Domain-swapped cytochrome cb562 dimer | homo-2-mer | 98.11 | 2×HEC; 7×ZN; 3×SO4; | |||
| Co-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presenc… | homo-2-mer | 90.57 | 2×HEC; 2×CO; | |||
| Ni(II)-bound B2 dimer (H60/H100/H104) | homo-2-mer | 93.4 | 2×HEC; 2×NI; 1×MPD; | |||
| Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2, crystallized in the presenc… | homo-2-mer | 90.57 | 2×HEC; 4×CA; 1×CU; | |||
| Co-bound crystal structure of the engineered cyt cb562 variant, AB2-H100A, crystallized in the pres… | homo-2-mer | 91.51 | 2×HEC; 1×CO; | |||
| Cu-bound crystal structure of the engineered cyt cb562 variant, DiCyt2 - H97A, crystallized in the … | homo-2-mer | 90.57 | 2×HEC; 3×CA; 1×CU; | |||
| Crystal structure of an engineered cytochrome cb562 that forms 1D, Zn-mediated coordination polymers | homo-2-mer | 86.79 | 2×HEM; 2×ZN; 1×CA; | |||
| Crystal structure of the dimeric assembly of the cyt cb562 variant RIDC-1 | homo-2-mer | 89.62 | 2×HEM; | |||
| Crystal structure of the Cu-induced dimer of the engineered cyt cb562 variant RIDC-1 | homo-2-mer | 89.62 | 2×HEM; 2×CU; 2×CL; | |||
| Crystal structure of an engineered cytochrome cb562 that forms 2D, Zn-mediated sheets | homo-2-mer | 86.79 | 2×HEM; 3×ZN; | |||
| Crystal Structure of a Ni-directed Dimer of Cytochrome cb562 with a Quinolate-Histidine Hybrid Coor… | homo-2-mer | 96.23 | 2×HEM; 2×HQI; 2×NI; | |||
| Apo B2 dimer (H60/H100/H104) formed in the presence of Cu(II) | homo-2-mer | 93.4 | 2×HEC; 2×SO4; | |||
| Structure of the human smoothened receptor in complex with SAG1.5 | homo-2-mer | 97.17 | 2×SG8; | |||
| A Multi-generation Analysis of Cytochrome b562 Redox Variants: Evolutionary Strategies for Modulati… | homo-2-mer | 97.17 | 3×MG; 2×HEM; | |||
| Structure of the human smoothened receptor in complex with SANT-1. | homo-2-mer | 97.17 | 2×NAG; 2×SNT; 4×ZN; 4×OLC; 2×PEG; 2×PG4; | |||
| Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with dihydroergotamine (PSI Com… | homo-2-mer | 96.81 | 2×2GM; | |||
| XFEL structure of human angiotensin II type 2 receptor (Monoclinic form) in complex with compound 1… | homo-2-mer | 99.0 | 2×8ES; | |||
| Synchrotron structure of human angiotensin II type 2 receptor in complex with compound 2 (N-[(furan… | homo-2-mer | 97.17 | 2×8EM; | |||
| Crystal Structure of a receptor in Complex with inverse agonist | homo-2-mer | 97.17 | 6×OLC; 2×1KQ; | |||
| Crystal structure of the non-ribose partial agonist LUF5833 bound to the adenosine A2A receptor | homo-2-mer | 96.43 | 2×RVZ; 8×OLA; 2×CLR; 2×NA; | |||
| Structure of the human smoothened 7TM receptor in complex with an antitumor agent | homo-2-mer | 98.09 | 2×1KS; 5×OLC; 3×OLA; 2×PEG; 1×PGE; 1×PG4; | |||
| Human class C G protein-coupled metabotropic glutamate receptor 1 in complex with a negative allost… | homo-2-mer | 97.14 | 2×FM9; 6×CLR; 1×OLA; 3×OLC; 2×PO4; | |||
| Crystal structure of the human prostaglandin E receptor EP3 bound to prostaglandin E2 | homo-2-mer | 100.0 | 2×P2E; 2×POV; | |||
| Crystal structure of the human adenosine A1 receptor A1AR-bRIL in complex with the covalent antagon… | homo-2-mer | 97.44 | 2×DU1; 7×OLA; | |||
| Crystal structure of dopamine receptor D4 bound to the subtype-selective ligand, L745870 | homo-2-mer | 97.75 | 2×L74; | |||
| Adenosine A2a receptor mutant-I92N | homo-2-mer | 98.84 | 2×UKA; | |||
| Human Consensus Olfactory Receptor OR52c in apo state, OR52c-bRIL | monomer | 20.0 | ||||
| Crystal structure of Xenopus Smoothened in complex with cyclopamine | monomer | 66.67 | 2×CY8; | |||
| Crystal structure of Xenopus Smoothened in complex with cholesterol | monomer | 66.67 | 1×CLR; | |||
| Cu(II)-bound structure of the engineered cyt cb562 variant, CH3Y | monomer | 92.45 | 1×HEC; 1×CU; | |||
| Crystal Structure of B562RIL with engineered disulfide bond T9C-A36C | monomer | 95.28 | ||||
| Co(II)-bound structure of the engineered cyt cb562 variant, CH3 | monomer | 93.4 | 1×CO; 1×HEC; | |||
| Crystal Structure of B562RIL with engineered disulfide bond K27C-A79C | monomer | 95.28 | ||||
| IMPROVEMENT OF THE 2.5 ANGSTROMS RESOLUTION MODEL OF CYTOCHROME B562 BY REDETERMINING THE PRIMARY S… | monomer | 100 | 2×SO4; 1×HEM; | |||
| Fe(II)-bound structure of the engineered cyt cb562 variant, CH3Y | monomer | 92.45 | 1×HEC; 1×FE; | |||
| Crystal Structure of B562RIL without disulfide bond | monomer | 97.17 | ||||
| Vanadyl-bound structure of the engineered cyt b562 variant, CH3Y* | monomer | 90.57 | 1×V; | |||
| Crystal Structure of B562RIL with engineered disulfide bond V16C-A29C | monomer | 95.28 | 4×SO4; | |||
| Cu(II)-bound structure of the engineered cyt cb562 variant, CH3 | monomer | 93.4 | 2×CA; 1×HEC; | |||
| Mn(II)-bound structure of the engineered cyt cb562 variant, CH2E | monomer | 93.4 | 2×MN; 1×HEC; | |||
| Crystal structure of the chimeric protein of A2aAR-BRIL in complex with ZM241385 at 1.8A resolution | monomer | 96.7 | 1×ZMA; 1×NA; 3×CLR; 16×OLA; 6×OLC; 1×OLB; 2×PEG; | |||
| A2AR crystallized in EROCOC17+4, LCP-SFX at 293 K | monomer | 96.7 | 1×ZMA; 1×NA; 3×CLR; 1×D12; 6×MYS; 1×HEX; 3×8K6; 1×D10; 3×OCT; 1×UND; 2×ER0; 4×TRD; | |||
| A2AR crystallized in EROCOC17+4, LCP-SFX at 277 K | monomer | 96.7 | 1×ZMA; 1×NA; 3×CLR; 1×D12; 6×MYS; 1×HEX; 3×8K6; 1×D10; 3×OCT; 1×UND; 2×ER0; 4×TRD; | |||
| CRYSTAL STRUCTURE OF B562RIL, A REDESIGNED FOUR HELIX BUNDLE | monomer | 97.17 | 1×SO4; | |||
| Vanadyl-bound structure of the engineered cyt cb562 variant, CH3Y | monomer | 92.45 | 1×V; 1×HEC; | |||
| XFEL A2aR structure by ligand exchange from LUF5843 to ZM241385. | monomer | 96.7 | 1×ZMA; 9×OLC; 3×CLR; 1×OLB; 13×OLA; 1×NA; | |||
| Mn(II)-bound structure of the engineered cyt cb562 variant, CH2EY | monomer | 92.45 | 1×HEC; | |||
| Fe(II)-bound structure of the engineered cyt cb562 variant, CH2E | monomer | 93.4 | 1×FE; 1×HEC; | |||
| Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.9A obtained from bespoke co-crystallisa… | monomer | 96.67 | 1×T4E; 4×CLR; 15×OLA; 11×OLC; 1×TAR; 1×PGE; 1×NA; | |||
| 1.9 angstrom A2a adenosine receptor structure with sulfur SAD phasing and phase extension using XFE… | monomer | 96.84 | 1×ZMA; 1×NA; 3×CLR; 10×OLC; 11×OLA; 1×PEG; | |||
| 1.9A angstrom A2a adenosine receptor structure with MR phasing using XFEL data | monomer | 96.81 | 1×ZMA; 1×NA; 3×CLR; 2×OLB; 8×OLC; 11×OLA; 1×PEG; | |||
| Iron- and Nitric Oxide-bound structure of the engineered cyt b562 variant, CH3Y* | monomer | 90.57 | ||||
| Iron-bound structure of the engineered cyt b562 variant, CH3Y* | monomer | 90.57 | 1×FE; | |||
| Co(II)-bound structure of the engineered cyt cb562 variant, H3 | monomer | 94.34 | 1×CO; 1×HEC; 1×CL; 6×CA; | |||
| Structure of the A2A-StaR2-bRIL562-LUAA47070 complex at 2.0A obtained from in meso soaking experime… | monomer | 96.7 | 1×9Y2; 1×NA; 4×CLR; 13×OLA; 10×OLC; | |||
| A2AR crystallized in EROCOC17+4, SS-ROX at 100 K | monomer | 96.7 | 1×ZMA; 1×NA; 3×CLR; 1×D12; 6×MYS; 1×HEX; 3×8K6; 1×D10; 3×OCT; 1×UND; 2×ER0; 4×TRD; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with theophylline… | monomer | 96.67 | 1×NA; 1×TEP; 3×CLR; 22×OLA; 7×OLC; | |||
| Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 1.86A obtained from in meso soaking exper… | monomer | 96.67 | 1×T4E; 1×NA; 4×CLR; 16×OLA; 11×OLC; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12f… | monomer | 96.67 | 1×NA; 1×6DZ; 1×HTO; 4×CLR; 19×OLA; 2×OLB; 4×OLC; | |||
| Crystal structure of the phenanthroline-modified cytochrome cb562 variant, MBP-Phen2 | monomer | 94.34 | 1×HEM; 1×PXX; 2×ACT; | |||
| Structure of the A2A-StaR2-bRIL562-Compound 4e complex at 2.1A obtained from in meso soaking experi… | monomer | 96.67 | 1×T4E; 1×NA; 14×OLA; 4×CLR; 12×OLC; 1×CL; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with caffeine at … | monomer | 96.77 | 1×NA; 1×CFF; 4×CLR; 18×OLA; 7×OLC; 1×TAR; | |||
| Crystal structure of orphan G protein-coupled receptor 6, pseudoapo form | monomer | 96.94 | 5×OLC; 2×P15; 12×OLA; 1×CLR; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with clinical can… | monomer | 96.63 | 1×NA; 1×U30; 4×CLR; 15×OLA; 3×OLB; 5×OLC; | |||
| Crystal structure of the adenosine A2A receptor (construct A2A-PSB2-bRIL) complexed with Etrumadena… | monomer | 96.59 | 1×U30; 3×CLR; 5×OLA; 2×OLC; 1×OLB; 1×PEG; | |||
| Crystal Structure of B562RIL with engineered disulfide bond A20C-Q25C | monomer | 95.28 | ||||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12b… | monomer | 96.67 | 1×NA; 1×6DX; 4×CLR; 17×OLA; 8×OLB; | |||
| XFEL crystal structure of the human sphingosine 1 phosphate receptor 5 in complex with ONO-5430608 | monomer | 98.85 | 1×NAG; 1×B2O; 3×OLC; | |||
| Crystal structure of E. coli cytochrome b562 with engineered c-type heme linkages | monomer | 97.17 | 1×SO4; 1×HEC; | |||
| Fe(II)-bound structure of the engineered cyt cb562 variant, CH3 | monomer | 93.4 | 1×FE; 1×HEC; 1×CA; | |||
| Crystal structure of the adenosine A2A receptor (A2A-PSB1-bRIL) in complex with preladenant conjuga… | monomer | 96.74 | 3×CLR; 1×8E2; 26×OLA; 3×OLC; 2×PEG; | |||
| Structure of human A2A adenosine receptor in complex with ZM241385 obtained from SFX experiments un… | monomer | 96.67 | 1×NA; 1×ZMA; 19×OLA; 3×CLR; | |||
| Crystal structure of human adenosine A2A receptor in complex with an insurmountable inverse agonist… | monomer | 96.67 | 1×JQR; 3×CLR; 18×OLC; 1×PE4; 1×NA; | |||
| 2.35-Angstrom In situ Mylar structure of human A2A adenosine receptor at 100 K | monomer | 96.7 | 1×ZMA; 1×NA; 3×CLR; 6×OLC; 10×OLA; 1×OLB; | |||
| Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2570366 (C2221 … | monomer | 96.39 | 1×KNW; 1×CLR; 1×TLA; 16×OLC; 10×OLA; 1×1PE; | |||
| Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2570366 (F222 s… | monomer | 96.51 | 1×KNW; 1×CLR; 2×OLC; 21×OLA; 1×PGE; | |||
| 2.5 angstrom A2a adenosine receptor structure with sulfur SAD phasing using XFEL data | monomer | 96.91 | 1×ZMA; 1×NA; 3×CLR; 10×OLC; 10×OLA; 1×PEG; | |||
| Crystal structure of A2AAR-StaR2-bRIL in complex with compound 21a | monomer | 96.77 | 1×TKO; 3×CLR; 4×OLC; 17×OLA; | |||
| Crystal structure of P2Y12 receptor in complex with 2MeSADP | monomer | 97.17 | 1×6AD; 1×CLR; 3×OLC; 1×PEG; | |||
| Crystal structure of the human thromboxane A2 receptor bound to ramatroban | monomer | 97.17 | 1×A8X; 1×ZN; 1×CLR; 2×OLC; 1×GOL; | |||
| 2.5 angstrom A2a adenosine receptor structure with MR phasing using XFEL data | monomer | 96.77 | 1×ZMA; 1×NA; 3×CLR; 1×OLB; 9×OLC; 8×OLA; | |||
| Crystal structure of A2AAR-BRIL in complex with the antagonist ZM241385 produced from Pichia pastor… | monomer | 96.7 | 1×ZMA; 3×CLR; 1×OLB; 7×OLA; 4×OLC; | |||
| XFEL crystal structure of the human cysteinyl leukotriene receptor 1 in complex with zafirlukast | monomer | 100 | 1×ZLK; 8×OLC; 11×OLA; 1×1PE; 1×NA; | |||
| Structure of the A2A-StaR2-bRIL562-Vipadenant complex at 2.6A obtained from in meso soaking experim… | monomer | 96.77 | 1×9XT; 15×OLA; 1×NA; 3×CLR; 8×OLC; | |||
| Crystal structure of the adenosine A2A receptor (A2A-PSB1-bRIL) in complex with preladenant conjuga… | monomer | 96.74 | 3×CLR; 1×8IM; 25×OLA; 4×OLC; 2×PEG; | |||
| Crystal structure of orphan G protein-coupled receptor 6 with bound inverse agonist 3h | monomer | 96.51 | 1×XY8; 1×NA; | |||
| Structure of the human smoothened receptor in complex with ANTA XV | monomer | 97.17 | 1×A8T; 1×ZN; | |||
| Structure of the human P2Y12 receptor in complex with an antithrombotic drug | monomer | 96.88 | 1×AZJ; 2×CLR; 2×OLC; | |||
| Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2080365 | monomer | 96.91 | 1×KNZ; 10×OLC; 3×OLA; | |||
| Crystal structure of 5-HT2C in complex with ritanserin | monomer | 95.31 | 1×E2J; 6×OLC; 1×PEG; 2×OLA; | |||
| Crystal structure of human GPCR Niacin receptor (HCA2) | monomer | 96.94 | 5×OLA; 1×OLC; 1×PEG; 5×UNX; | |||
| Crystal structure of the chimeric protein of 5-HT2B-BRIL in complex with ergotamine | monomer | 96.67 | 1×ERM; 1×PLM; 1×CLR; 1×OLC; 3×OLB; 2×OLA; 2×PEG; | |||
| Crystal structure of cysteinyl leukotriene receptor 1 in complex with pranlukast | monomer | 100 | 1×KNT; 1×NA; 9×OLC; 1×OLA; | |||
| Crystal structure of 5-HT2AR in complex with (R)-IHCH-7179 | monomer | 97.5 | 1×MG; 1×EZX; 7×OLC; 2×CLR; 1×1PE; 2×PEG; | |||
| XFEL structure of the human delta opioid receptor in complex with a bifunctional peptide | monomer | 97.17 | 3×OLA; 1×NA; 2×OLC; | |||
| Crystal structure of the chimeric protein of 5-HT1B-BRIL in complex with ergotamine (PSI Community … | monomer | 97.17 | 1×ERM; 1×OLB; | |||
| Crystal structure of the human cysteinyl leukotriene receptor 2 in complex with ONO-2770372 | monomer | 96.39 | 1×KO5; 1×CLR; 1×1PE; 13×OLC; 7×OLA; | |||
| Metal-free structure of the engineered cyt cb562 variant, CH3 | monomer | 93.4 | 1×HEC; 4×CA; | |||
| Cytochrome b562 integral fusion with EGFP | monomer | 100 | 1×HEM; | |||
| Crystal structure of the P2Y12 receptor in complex with the inverse agonist selatogrel. | monomer | 96.88 | 1×7Y5; 1×CLR; | |||
| Crystal structure of a zinc mediated dimer for the phenanthroline-modified cytochrome cb562 variant… | monomer | 94.34 | 1×HEM; 1×PXX; | |||
| Crystal structure of the 5-HT2B receptor solved using serial femtosecond crystallography in lipidic… | monomer | 96.39 | 1×PLM; 1×ERM; 1×CLR; 4×OLC; 1×PEG; 1×TRS; 3×OLA; 2×DGA; | |||
| Crystal structure of the chimeric protein of A2aAR-BRIL with bound iodide ions | monomer | 96.63 | 1×ZMA; 3×CLR; 6×IOD; 2×PEG; 4×OLA; 6×OLC; 1×OLB; | |||
| Crystal structure of the human formyl peptide receptor 2 in complex with WKYMVm | monomer | 97.17 | 2×CLR; | |||
| XFEL structure of human angiotensin II type 2 receptor (Orthorhombic form) in complex with compound… | monomer | 97.17 | 1×8ES; 1×OLC; 1×OLA; | |||
| Crystal structure of 5-HT2AR in complex with zotepine | monomer | 97.5 | 1×ZOT; 1×CLR; 1×1PE; 1×ZN; | |||
| Crystal structure of the LSD-bound 5-HT2B receptor | monomer | 98.95 | 1×7LD; 1×CLR; 1×OLC; 1×PEG; 1×PO4; | |||
| Crystal structure of 5-HT2AR in complex with aripiprazole | monomer | 97.5 | 3×CLR; 1×1PE; 4×OLC; 1×9SC; 1×MG; | |||
| A Triangular Cytochrome b562 Superstructure Mediated by Ni Coordination - Hexagonal Form | monomer | 93.4 | 1×HEM; 1×PXX; 2×NI; | |||
| Crystal structure of the human thromboxane A2 receptor bound to daltroban | monomer | 97.17 | 1×A90; 1×ZN; 1×CLR; 1×GOL; | |||
| Crystal structure of 5-HT2C in complex with ergotamine | monomer | 96.74 | 1×ERM; 1×OLC; | |||
| Crystal structure of 5-HT2AR in complex with risperidone | monomer | 97.5 | 1×8NU; 1×CLR; 1×ZN; 3×1PE; | |||
| Crystal structure of the angiotensin II type 2 receptoror (AT2R) in complex with EMA401 | monomer | 97.17 | 1×VFD; 3×OLC; 3×OLA; 1×FMT; 1×HEZ; | |||
| Crystal structure of a nickel mediated dimer for the phenanthroline-modified cytochrome cb562 varia… | monomer | 94.34 | 1×HEM; 1×PXX; | |||
| XFEL crystal structure of human melatonin receptor MT2 (N86D) in complex with 2-phenylmelatonin | monomer | 97.17 | 1×JEY; 1×ZN; | |||
| Crystal structure of P2Y12 receptor in complex with 2MeSATP | monomer | 97.17 | 1×6AT; 2×OLC; | |||
| Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor | monomer | 96.47 | 1×CLR; 1×OLC; 1×PEG; 1×H8M; | |||
| XFEL crystal structure of human melatonin receptor MT2 (H208A) in complex with 2-phenylmelatonin | monomer | 97.17 | 1×JEY; 1×ZN; | |||
| Serial Millisecond Crystallography of Membrane and Soluble Protein Micro-crystals using Synchrotron… | monomer | 96.67 | 1×ZMA; 3×CLR; 2×OLC; 1×OLA; | |||
| Human Smoothened Receptor structure in complex with cyclopamine | monomer | 97.17 | 1×CY8; | |||
| XFEL crystal structure of human melatonin receptor MT2 in complex with ramelteon | monomer | 97.17 | 1×JEV; 1×ZN; | |||
| Crystal structure of 5-HT2AR in complex with cariprazine | monomer | 97.5 | 1×MG; 3×CLR; 3×OLC; 1×7RU; | |||
| Structure of the class B human glucagon G protein coupled receptor | monomer | 97.17 | 1×PEG; | |||
| Crystal structure of an inverse agonist antipsychotic drug pimavanserin-bound 5-HT2A | monomer | 97.5 | 1×A1L11; | |||
| Crystal structure of HTR2A with hallucinogenic agonist | monomer | 96.97 | 1×7LD; 2×CLR; 2×OLA; 1×PEG; | |||
| Crystal structure of HTR2A with inverse agonist | monomer | 96.91 | 1×89F; 2×OLA; 1×CLR; 1×PEG; | |||
| Room-temperature structure of the stabilised A2A-Theophylline complex determined by synchrotron ser… | monomer | 96.67 | 1×TEP; 3×CLR; 3×OLA; 2×OLC; 1×NA; | |||
| Crystal structure of orphan G protein-coupled receptor 6 with bound CVN424 | monomer | 96.67 | 1×X7T; | |||
| Crystal structure of adenosine A2A receptor bound to a novel triazole-carboximidamide antagonist | monomer | 96.97 | 1×EDT; 1×MES; 1×8D1; | |||
| Room-temperature structure of the stabilised A2A-LUAA47070 complex determined by synchrotron serial… | monomer | 96.67 | 1×9Y2; 3×CLR; 4×OLA; 1×NA; | |||
| Crystal structure of an inverse agonist antipsychotic drug derivative-bound 5-HT2C | monomer | 93.88 | 1×A1L10; | |||
| SOLUTION STRUCTURE OF OXIDIZED ESCHERICHIA COLI CYTOCHROME B562 | monomer | 100 | 1×HEM; | |||
| THE SOLUTION STRUCTURE OF THE HEME BINDING VARIANT ARG98CYS OF OXIDIZED ESCHERICHIA COLI CYTOCHROME… | monomer | 99.06 | 1×HEB; | |||
| SOLUTION STRUCTURE OF APOCYTOCHROME B562 | monomer | 100 | ||||
| CryoEM structure of the adenosine 2A receptor-BRIL/Anti BRIL Fab complex with ZM241385 | monomer | 96.67 | 1×ZMA; | |||
| cryo-EM structure of the beta2-AR-mBRIL/1b3 Fab/Glue complex with a full agonist | monomer | 97.67 | 1×DZQ; | |||
| Cryo-EM structure of the beta2AR-mBRIL/1b3 Fab/Glue complex with a partial agonist | monomer | 97.67 | 1×H98; | |||
| MicroED structure of the human adenosine receptor at 2.8A | monomer | 96.7 | 1×ZMA; 4×CLR; 1×NA; | |||
| A2A Adenosine receptor room-temperature structure determined by serial femtosecond crystallography | monomer | 97.67 | 5×OLA; 1×NA; 1×ZMA; 3×CLR; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with ZM241385 at … | monomer | 97.78 | 1×NA; 1×ZMA; 4×CLR; 20×OLA; 3×OLB; 2×OLC; | |||
| 1.8 A Structure of the human delta opioid 7TM receptor (PSI Community Target) | monomer | 97.14 | 12×OLA; 5×OLC; 3×PGE; 1×TLA; 1×EJ4; 1×NA; | |||
| Structure of the A2A-StaR2-bRIL562-ZM241385 complex at 1.86A obtained from in meso soaking experime… | monomer | 97.83 | 1×ZMA; 4×CLR; 17×OLA; 4×SCN; 3×OLC; 1×CIT; 1×NA; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12c… | monomer | 97.78 | 1×NA; 1×6DY; 4×CLR; 18×OLA; 7×OLB; 1×OLC; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with Chromone 4d | monomer | 97.67 | 1×QGE; 1×NA; 3×CLR; 11×OLA; 4×OLC; | |||
| A2A Adenosine receptor cryo structure | monomer | 97.78 | 1×NA; 1×ZMA; 15×OLA; 2×OLB; 2×OLC; 3×CLR; | |||
| Structure of the human D4 Dopamine receptor in complex with Nemonapride | monomer | 97.09 | 1×AQD; 3×PO4; 9×OLA; 9×PEG; 1×GOL; | |||
| 2.0A angstrom A2a adenosine receptor structure using XFEL data collected in helium atmosphere. | monomer | 97.75 | 1×NA; 1×ZMA; 3×CLR; 15×OLA; 5×OLC; 1×GOL; 1×OLB; | |||
| Crystal Structure of the A2A-StaR2-bRIL562 in complex with AZD4635 at 2.0A resolution | monomer | 97.78 | 1×NA; 1×F9Q; 3×CLR; 15×OLA; 10×OLC; | |||
| Crystal structure of A2AAR-StaR2-bRIL in complex with a novel A2a antagonist, LJ-4517 | monomer | 97.85 | 4×PEG; 1×LJX; 1×NA; 7×OLC; 23×OLA; 3×CLR; 1×ETF; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with compound 12x… | monomer | 97.78 | 1×NA; 1×6DV; 3×CLR; 16×OLA; 7×OLB; 2×OLC; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with Chromone 5d | monomer | 97.65 | 1×QGW; 1×NA; 3×CLR; 1×OLB; 14×OLA; 1×OLC; | |||
| A2A Adenosine receptor room-temperature structure determined by serial millisecond crystallography | monomer | 97.67 | 3×OLA; 1×NA; 1×ZMA; 3×CLR; | |||
| Structure of the sodium-bound human D4 Dopamine receptor in complex with Nemonapride | monomer | 97.14 | 1×AQD; 5×PO4; 8×OLA; 9×PEG; 1×NA; | |||
| Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with NMS | monomer | 98.09 | 1×3C0; | |||
| In meso structure of the adenosine A2a G protein-coupled receptor, A2aR, in 7.10 monoacylglycerol | monomer | 97.78 | 1×ZMA; 3×CLR; 8×A1H2K; 1×A1H52; 2×GOL; 1×NA; | |||
| Crystal structure of human adenosine A2A receptor (construct A2A-PSB2-bRIL) complexed with the part… | monomer | 97.73 | 3×CLR; 4×OLA; 3×OLC; 1×OLB; 1×PEG; 1×A1H1S; | |||
| Crystal structure of serotonin 2A receptor in complex with lumateperone | monomer | 97.5 | 1×MG; 4×CLR; 1×1PE; 11×OLC; 1×92S; 1×PEG; | |||
| Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with NM… | monomer | 98.09 | 1×3C0; 3×HG; | |||
| Crystal structure of serotonin 2A receptor in complex with non-hallucinogenic psychedelic analog | monomer | 97.5 | 1×MG; 3×CLR; 6×OLC; 1×93F; 1×1PE; 2×PEG; | |||
| Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with QNB | monomer | 98.09 | 1×QNB; | |||
| Crystal structure of serotonin 2A receptor in complex with LSD | monomer | 97.5 | 1×MG; 1×CLR; 4×OLC; 1×7LD; 1×1PE; 3×PEG; | |||
| Crystal structure of serotonin 2A receptor in complex with lisuride | monomer | 97.5 | 1×MG; 1×CLR; 1×1PE; 5×OLC; 3×PEG; 1×H8G; | |||
| Structure of the A2A adenosine receptor determined at SwissFEL using native-SAD at 4.57 keV from 50… | monomer | 97.78 | 1×ZMA; 7×OLA; 2×OLB; 2×OLC; 3×CLR; | |||
| Crystal structure of human alkaline ceramidase 3 (ACER3) at 2.7 Angstrom resolution | monomer | 98.09 | 1×ZN; 6×SO4; 3×NA; 1×OLB; 1×CA; 2×MG; | |||
| Crystal structure of human GPCR Niacin receptor (HCA2) expressed from Spodoptera frugiperda | monomer | 97.85 | 6×OLA; 1×OLC; | |||
| Crystal Structure of Human Angiotensin Receptor in Complex with Inverse Agonist Olmesartan at 2.8A … | monomer | 97.14 | 1×OLM; | |||
| Crystal structure of A2AAR-StaR2-S277-bRIL in complex with a novel A2a antagonist, LJ-4517 | monomer | 97.85 | 16×OLA; 3×OLC; 1×PEG; 1×LJX; 3×CLR; | |||
| Crystal structure of stabilized A2A adenosine receptor A2AR-StaR2-bRIL in complex with PSB36 at 2.8… | monomer | 97.78 | 1×NA; 1×8JN; 3×CLR; 21×OLA; 5×OLC; 1×TAR; | |||
| Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with … | monomer | 98.09 | 1×8TZ; 1×NA; 1×PO4; | |||
| Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-9910539 | monomer | 97.62 | 1×ON9; 1×1WV; | |||
| Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allo… | monomer | 97.78 | 1×9P2; | |||
| Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO-3080573 | monomer | 97.62 | 1×ON3; 1×1WV; | |||
| Crystal structure of rationally thermostabilized M2 muscarinic acetylcholine receptor bound with AF… | monomer | 97.98 | 1×82F; | |||
| Crystal structure of M2 muscarinic acetylcholine receptor bound with NMS | monomer | 97.89 | 1×3C0; | |||
| Structure of human Smoothened in complex with cholesterol and SAG | monomer | 97.96 | 1×V0S; 1×CLR; 1×NAG; 2×NA; 1×MPG; | |||
| Crystal Structure of Human Lysophosphatidic Acid Receptor 1 in complex with ONO9780307 | monomer | 97.62 | 1×ON7; 1×1WV; | |||
| Structure of the A2A-StaR2-bRIL562-Tozadenant complex at 3.1A obtained from in meso soaking experim… | monomer | 97.7 | 1×9XW; 3×CLR; 10×OLA; 8×OLC; 1×NA; | |||
| Structure of human Smoothened in complex with cholesterol | monomer | 97.94 | 2×NAG; 1×CLR; 2×NA; | |||
| Synchrotron structure of the human delta opioid receptor in complex with a bifunctional peptide (PS… | monomer | 97.14 | 1×OLC; | |||
| Structure of human Smoothened in complex with Vismodegib | monomer | 97.75 | 1×NAG; 1×VIS; | |||
| Crystal structure of a thermostabilised human protease-activated receptor-2 (PAR2) in complex with … | monomer | 98.09 | 1×8UN; 1×NA; | |||
| High-viscosity injector-based Pink Beam Serial Crystallography of Micro-crystals at a Synchrotron R… | monomer | 97.75 | 1×ZMA; | |||
| The solution structure of a redesigned apocytochrome B562 (Rd-apocyt b562) with the N-terminal heli… | monomer | 92.38 | ||||
| Cryo-EM structure of the beta2AR-mBRIL/1b3 Fab/Glue complex with an antagonist | monomer | 97.67 | 1×JTZ; | |||
| MicroED structure of A2A from plasma milled lamellae | monomer | 97.78 | 1×ZMA; 3×CLR; 15×OLA; 5×OLC; 1×OLB; 1×NA; | |||
| Crystal structure of human C5a receptor in complex with an orthosteric antagonist PMX53 and an allo… | monomer | 98.77 | 1×EFD; 2×MLI; 1×NA; 1×PGE; 2×OLC; 4×OLA; | |||
| XFEL structure of human Angiotensin Receptor | monomer | 98.08 | 1×ZD7; | |||
| The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with C-35 (PSI Co… | monomer | 97.11 | 1×DGV; 1×OLC; 2×OLA; | |||
| The crystal structure of nociceptin/orphanin FQ peptide receptor (NOP) in complex with SB-612111 (P… | monomer | 97.11 | 2×OLA; 1×DGW; 1×OLC; | |||
| Crystal structure of stabilized A1 receptor in complex with PSB36 at 3.3A resolution | monomer | 98.06 | 1×8K8; 2×SO4; | |||
| Structure of MurJ from Escherichia coli | monomer | 98.08 | 1×PO4; | |||
| The solution structure of a redesigned apocytochrome B562 (Rd-apocyt b562) with the N- and a part o… | monomer | 91.35 | ||||
| Structure of A2A adenosine receptor A2AR-StaR2-bRIL, solved at wavelength 2.75 A | monomer | 98.82 | 1×TEP; 12×OLA; 3×CLR; | |||
| Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor | monomer | 98.95 | 1×H8D; 1×CLR; 1×OLA; 1×OLC; 1×PEG; 2×PO4; | |||
| Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor | monomer | 98.7 | 1×H8G; 1×CLR; 1×OLC; | |||
| Structural Determinants of Activation and Biased Agonism at the 5-HT2B Receptor | monomer | 98.86 | 1×CLR; 1×OLA; 1×OLC; 1×PEG; 1×PO4; 1×H8J; | |||
| Crystal structure of a peptidergic GPCR in complex with a small synthetic G protein-biased agonist | monomer | 98.96 | 1×A1D5N; 6×OLA; 1×1PE; | |||
| Human Consensus Olfactory Receptor OR52c in apo state, OR52c only | monomer | 20.0 | ||||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 3u8p.1.A | monomer | 0.83 | 91.38 | |||
| 1yza.1.A | monomer | 0.53 | 91.51 | |||